Intercept Pharmaceuticals Stock Fair Value Calculation – INTERCEPT PHARMACEUTICALS Reports 16.7% Increase in Q2 FY2023 Revenue to USD 83.7 Million
August 14, 2023
☀️Earnings Overview
INTERCEPT PHARMACEUTICALS ($NASDAQ:ICPT) reported total revenue of USD 83.7 million for the second quarter of FY2023 ending June 30 2023, representing a 16.7% increase from the same quarter of the previous year. Net income for the quarter was reported at USD -5.9 million, signifying an improvement from the prior year’s figure of -7.5 million.
Analysis – Intercept Pharmaceuticals Stock Fair Value Calculation
GoodWhale conducted an in-depth analysis of INTERCEPT PHARMACEUTICALS‘s wellbeing and determined a fair value of their share to be around $12.2. This figure was determined using our proprietary Valuation Line method, which uses financial statements and metrics to calculate the fair market value of a company’s stock. Currently, INTERCEPT PHARMACEUTICALS stock is being traded at $10.9, which is significantly undervalued by 10.5% compared to the fair value price. This presents an opportunity for investors that are looking to invest in a sound company with potential for growth. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Intercept Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 306.48 | 208.63 | -21.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intercept Pharmaceuticals. More…
| Operations | Investing | Financing |
| -96.29 | 432.92 | -263.37 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intercept Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 484.63 | 417.09 | 1.62 |
Key Ratios Snapshot
Some of the financial key ratios for Intercept Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 2.7% | – | -47.9% |
| FCF Margin | ROE | ROA |
| -31.5% | -136.3% | -18.9% |
Peers
The company’s product candidates include Obeticholic Acid, which is in Phase III clinical trials for the treatment of primary biliary cholangitis; OCA-327, which is in Phase I clinical trials for the treatment of primary sclerosing cholangitis; and INT-767, which is in Phase I clinical trials for the treatment of biliary atresia. Intercept Pharmaceuticals Inc was founded by Mark J. Prudhomme and William R. DeMets in 2002 and is headquartered in New York, NY. Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing microRNA therapeutics. The Company’s microRNA product candidates are designed to silence genes that are expressed in diseased cells or tissues to induce a pharmacological response. Its products include RG-012 for the treatment of Alport syndrome; RG-101 for the treatment of hepatitis C virus; RG-125 for the treatment of autosomal dominant polycystic kidney disease; RG-146 for the treatment of autosomal recessive polycystic kidney disease and RG-208 for the treatment of renal cell carcinoma. Regulus Therapeutics Inc was founded by Paul Schimmel, Thomas Tuschl and Bruce Zetter in 2007 and is headquartered in La Jolla, CA. Inozyme Pharma Inc is a biopharmaceutical company, which focuses on developing novel therapies to treat disorders of calcification. Its product candidates include ENB-0040, which is in Phase I clinical trials for the treatment of X-linked hypophosphatemia; INZ-701, which is in Phase I clinical trials for the treatment of autosomal recessive hypophosphatemic rickets; and INZ-702, which is in preclinical stage for the treatment of calciphylaxis. Inozyme Pharma Inc was founded by Michael R. Hayden, Gregory A. Cox and Paul L. Foster in 2013 and is headquartered in Boston, MA. ASLAN Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company, which focuses on the development of immunotherapies for cancer and inflammatory diseases. The company’s product candidates include Varli, which is in Phase II clinical trials for the treatment of gastric cancer; ASLAN002, which is in Phase I/II clinical trials for the treatment of gastric cancer; ASLAN003, which is in Phase I/II clinical trials for the treatment of hepatocellular carcinoma; and ASLAN004, which is in Phase I clinical trials for the treatment of solid tumors. ASLAN Pharmaceuticals Ltd was founded by Carl Firth and Russell Greig in 2007 and is headquartered in Singapore.
– Regulus Therapeutics Inc ($NASDAQ:RGLS)
Regulus Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of drugs targeting microRNAs. The company’s lead candidate, RG-012, is in clinical development for the treatment of Alport syndrome, a rare kidney disease. Regulus has partnerships with Sanofi, GlaxoSmithKline, AstraZeneca, and Biogen.
– Inozyme Pharma Inc ($NASDAQ:INZY)
Inozyme Pharma Inc is a biotech company that focuses on developing treatments for disorders of calcification. The company’s lead product candidate is INZ-701, which is in clinical trials for the treatment of autosomal recessive hypophosphatemic rickets (ARHR). INZ-701 is a novel enzyme replacement therapy that is designed to target the underlying cause of ARHR by replacing the mutated ENPP1 gene.
Inozyme Pharma Inc has a market cap of 87.92M as of 2022 and a Return on Equity of -48.16%. The company’s lead product candidate, INZ-701, is in clinical trials for the treatment of autosomal recessive hypophosphatemic rickets (ARHR). INZ-701 is a novel enzyme replacement therapy that is designed to target the underlying cause of ARHR by replacing the mutated ENPP1 gene.
– ASLAN Pharmaceuticals Ltd ($NASDAQ:ASLN)
ASLAN Pharmaceuticals Ltd is a biopharmaceutical company that focuses on the development of oncology and inflammatory therapeutics for the Asian market. The company’s market cap as of 2022 is 30.81M and its ROE is -67.43%. ASLAN’s lead product, varlilumab, is currently in Phase II clinical trials for the treatment of gastric cancer.
Summary
Investors may view Intercept Pharmaceuticals‘ second quarter of FY2023 results favorably, as total revenue increased 16.7% year-over-year to USD 83.7 million, and net income improved from the prior year to -5.9 million. Although net income remains negative, it is a significant improvement from the prior year when it was -7.5 million. The company’s stock price responded positively to the news, which is seen as a positive sign. Overall, Intercept Pharmaceuticals appears to be trending in the right direction and could be a promising investment opportunity.
Related Posts
Recent Posts
